Retrospective Cohort Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Nov 7, 2018; 24(41): 4698-4707
Published online Nov 7, 2018. doi: 10.3748/wjg.v24.i41.4698
Table 4 Overview of patients with metastatic T1b OAC
CaseEMR tumour histopathologyTreatment after index EMRTime till metastases (mo)1Additional treatmentEnd study outcomeCause of deathSurvival2 (mo)
1Sm2/3, G3, LVIX, R1Surgery4ChemotherapyDeceasedOAC45
2SmX, G3, LVI+, R1Surgery2NoneAlive/87
3SmX, G3, LVI+, R1Surgery4CRTDeceasedOAC8
4Sm2/3, G3, LVI+, R1Surgery2ChemotherapyAlive/55
5Sm2/3, G3, LVIX, R1Conservative38CRTDeceasedOAC40
6Sm2/3, G2, LVI+, R1Conservative4CRTDeceasedOAC9
7Sm2/3, G2, LVI-, R1Conservative3CRTDeceasedOAC31
8Sm2/3, G2, LVI+, R1Conservative4CRTDeceasedOAC18
9Sm1, G2, LVI-, R1Conservative17EMR T1a, CRTAlive/26
10Sm2/3, G3, LVI-, R1Conservative13RadiotherapyDeceasedOAC30